ISLL has also filed 2 new patents and is in the process of developing non-infringing processes for 6 new molecules. The company is planning a capital expenditure of $15 million in the next three years.
V K Mehta, managing director, ISLL, told Business Standard that in addition to existing 15 products, the company has 20 products in pipeline with a combined global sales of approximately $18 billion in 2002. ISLL envisages being among the top three Indian companies to launch them.
Of these, about 4 to 5 products are slated to be commercially launched during the current year. The new products are an anti-alcoholic drug (sales of $16.2 million in the UK), a molecule for breast cancer (a $100 million product) and the company will be the first in India to launch a molecule for protozoan and helminth infection, he said.
The company is also going to launch two molecules from its Statins range, which include an anti-hyperlipidenic drug with world market of over $50 billion by 2005.
ISLL will be the third company globally to launch this product. It is planning a capital expenditure of over around $15 million in the next three years.
The expenditure will be incurred on setting up a new FDA dosage form facility with a total investment of $10 million, upgrading existing API facilities, bio-batch facility for meeting future regulatory demand, R&D infrastructure as per regulatory requirement and contract research activities.
The company is also in the process of developing non-infringing processes for the blockbusters going off-patent in next 5-10 years, as well as those molecules, which don
